June 6, 2022 12:53 PM EDTUpdated 02:10 PM

#ASCO22: Playing catch-up with Lumakras: Mirati touts CNS-specific activity that analysts think pad the case for approval

CHICAGO — Mirati Therapeutics is pulling out all the stops to beef up its case for adagrasib, as the biotech could be 18 months behind …

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

#AS­CO22: Play­ing catch-up with Lumakras: Mi­rati touts CNS-spe­cif­ic ac­tiv­i­ty that an­a­lysts think pad the case for ap­proval